Standard Biotools (LAB) Capital Expenditures Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Standard Biotools | 448.37 Mn | -6.80 Mn | 11.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45.96% |
| Dec 31, 2025 | -21.53% |
| Sep 30, 2025 | 21.18% |
| Jun 30, 2025 | 24.10% |
| Mar 31, 2025 | 37.45% |
| Dec 31, 2024 | 11.94% |
| Sep 30, 2024 | -27.16% |
| Jun 30, 2024 | 35.83% |
| Mar 31, 2024 | 24.04% |
| Dec 31, 2023 | -168.54% |
| Sep 30, 2023 | 35.52% |
| Jun 30, 2023 | 61.19% |
| Mar 31, 2023 | 67.33% |
| Dec 31, 2022 | 33.51% |
| Sep 30, 2022 | 17.94% |
| Jun 30, 2022 | 45.88% |
| Mar 31, 2022 | 4.64% |
| Dec 31, 2021 | -6.35% |
| Sep 30, 2021 | 49.59% |
| Jun 30, 2021 | 48.86% |
| Mar 31, 2021 | 43.34% |
| Dec 31, 2020 | 49.43% |
| Sep 30, 2020 | 7.60% |
| Jun 30, 2020 | -14.48% |
| Mar 31, 2020 | 2.53% |
| Dec 31, 2019 | -19.55% |
| Sep 30, 2019 | -0.15% |
| Jun 30, 2019 | -31.36% |
| Mar 31, 2019 | -31.88% |
| Dec 31, 2018 | -59.70% |
| Sep 30, 2018 | -21.23% |
| Jun 30, 2018 | -18.49% |
| Mar 31, 2018 | -35.65% |
| Dec 31, 2017 | -25.26% |
| Sep 30, 2017 | 7.72% |
| Jun 30, 2017 | -29.95% |
| Mar 31, 2017 | 11.75% |
| Dec 31, 2016 | 0.44% |
| Sep 30, 2016 | 43.28% |
| Jun 30, 2016 | 25.17% |
| Mar 31, 2016 | 39.06% |
| Dec 31, 2015 | 28.57% |
| Sep 30, 2015 | -13.02% |